First signs of clinical benefit in adjuvant head and neck cancer reported at AACR 2024, paved the way for the start of Phase II part of randomized Phase I/II clinical trial in Q2 2024 – Median ...

We are excited to see efti in combination with KEYTRUDA now driving a 1.9-fold increase in responses ... The ESMO Proferred ...

Results from triple combination of efti, radiotherapy and KEYTRUDA® (pembrolizumab) to be presented at the Connective Tissue Oncology Society ...

PDS Biotechnology's HPV-directed immunotherapy is sparking optimism in the biotech industry. Click here to find out why I am ...

Median Overall Survival remains at 30 months; Objective Response Rate of 36% and Disease Control Rate of 77% 11/53 (21%) of patients experienced 90-100% tumor shrinkage VERSATILE-003 Phase 3 clinical ...

CY-101 well tolerated with early signs of clinical activity, especially in tumors with dysregulated Wnt/β-catenin signalling CY-101 granted Orphan Drug Designation in US for the treatment of ...

Cytovation to present safety and efficacy data from CICILIA phase I/IIa clinical trial evaluating CY-101 in solid tumors: Bergen, Norway Monday, September 16, 2024, 18:00 Hrs [IST ...

PADCEV + KEYTRUDA**: additional analysis from the pivotal EV-302 ... PF-07104091 in HR+ HER2- metastatic breast cancer and advanced solid tumors Yap et al Poster Presentation (Abstract 413P) Monday, ...

The recent ESMO 2024 data highlighted significant advancements in immunotherapy. Check out the results from Merck, BMY, ...

PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the ...

Danish clinical-stage techbio firm Evaxion Biotech,which is developing AI-Immunology powered vaccines, announced new clinical ...